StockData
MediWound Ltd. logo

MediWound Ltd. (MDWD) company profile

MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$13.55+0.65 (+5.04%)

Close on Nov 16, 2026Market cap $173.92MP/E –Yield –

About MediWound

Medicinal Chemicals & Botanical Products, SIC 2833

MediWound Ltd. is a biopharmaceutical company that develops and commercializes therapeutics for burn care and wound management. Its primary products and pipeline product candidates include NexoBrid and EscharEx. The company serves healthcare providers and institutional partners, collaborating with government organizations such as the United States Biomedical Advanced Research and Development Authority, commercial pharmaceutical partners including Vericel and Teva, and regional burn centers and medical units.

The company is headquartered in Yavne, Israel, where it is also incorporated. Its operational scale and geographic presence span multiple countries, including the United States, Israel, and several European nations such as Germany, Italy, and Spain. MediWound operates dedicated manufacturing facilities to produce intermediate drug substances and finished goods for its research programs, clinical trials, and international commercial supply.

Summary of the business section of MediWound's latest annual report, written by StockData.

Company profile

Company

Legal name
MediWound Ltd.
Headquarters
Yavne, L3
Address
42 Hayarkon Street 8122745
Phone
972779714100
Employees
35, Dec 31, 2025
Industry
Medicinal Chemicals & Botanical Products
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Somekh Chaikin, Tel Aviv, Israel

Stock & identifiers

Ticker
MDWD
Exchange
Nasdaq
IPO date
Mar 21, 2014
Shares outstanding
13M, Dec 31, 2025
Filer category
Accelerated filer
Stock splits
1-for-7 reverse, Dec 20, 2022
SEC CIK
1593984
CUSIP
M68830104
FIGI
BBG005ZPKRQ4
Share class FIGI
BBG005ZPKSG3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ofer GonenChief Executive Officer66,019
Shmuel HessCOO & Chief Commercial Officer0
Ety KlingerChief Medical Officer1,500
Yaron MeyerEVP, GC & Corp. Secretary2,357
Yaakov Aya BenVP Clinical & Reg. Affairs125
Kalfon Hana LuxenburgChief Financial Officer3,000
Nachum ShamirDirector72,151
David Morton FoxDirector28,817
Samuel RubinsteinDirector750
Vickie Rae DriverDirector750
Stephen T. WillsDirector750

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 21, 2014
Offer price
$14.00
Securities offered
5,000,000
Gross proceeds
$70.00M
Exchange
Nasdaq
First trading day
Mar 20, 2014
First-day close
$17.27+23.4%
Lock-up ends (est.)
Sep 16, 2014

“Our ordinary shares have been approved for listing on the NASDAQ Global Market under the symbol "MDWD." Per Share Total Public offering price $ 14.00 $ 70,000,000 Underwriting discount(1) $ 0.98 $ 4,900,000 Proceeds, before expenses, to us $ 13.02 $ 65,100,000 (1) See "Underwriting" for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“Our research and development team is located at our facilities in Yavne and Gan-Rave, Israel, and consists of 35 employees as of December”

Corporate history

Events identified from SEC filings

See a number that looks wrong?